Inhaled Amphotericin B Lipid Complex for Prophylaxis Against COVID-19-associated Invasive Pulmonary Aspergillosis
link.springer.com
Recently, Prattes and colleagues published in Intensive Care Medicine a high incidence of coronavirus disease 2019-associated invasive pulmonary aspergillosis (CAPA), according to 2020 ECMM/ISHAM consensus criteria, with a correspondingly high mortality rate.
However, both the guidelines and a Taskforce report published recently only considered host risk factors.
Many work-related aspergillosis outbreaks have been reported due to airborne contamination with Aspergillus spores.
Protective measures against environmental contamination must be taken when there is construction activity on-site in a hospital.
Antifungal prophylaxis is not recommended in mechanical ventilated patients affected by coronavirus disease 2019 (COVID-19).